Astal Laboratories Ltd
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]
- Market Cap ₹ 299 Cr.
- Current Price ₹ 68.2
- High / Low ₹ 103 / 60.4
- Stock P/E 20.3
- Book Value ₹ 79.1
- Dividend Yield 0.00 %
- ROCE 9.13 %
- ROE 7.96 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.86 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 4.53%
- Company has high debtors of 229 days.
- Promoter holding has decreased over last 3 years: -63.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 64 | 249 | |
| 51 | 228 | |
| Operating Profit | 13 | 21 |
| OPM % | 20% | 8% |
| 0 | 0 | |
| Interest | 1 | 2 |
| Depreciation | 0 | 1 |
| Profit before tax | 12 | 18 |
| Tax % | 25% | 17% |
| 9 | 15 | |
| EPS in Rs | 9.08 | 3.48 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 288% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 51% |
| 3 Years: | 28% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10 | 42 |
| Reserves | 26 | 292 |
| 13 | 50 | |
| 14 | 135 | |
| Total Liabilities | 63 | 518 |
| 11 | 268 | |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| 52 | 251 | |
| Total Assets | 63 | 518 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Net Cash Flow | ||
| Free Cash Flow | ||
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 157 | 229 |
| Inventory Days | 112 | 113 |
| Days Payable | 82 | 206 |
| Cash Conversion Cycle | 187 | 135 |
| Working Capital Days | 97 | 114 |
| ROCE % | 9% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Interest Income (Financial/Lending Business phase) ₹ Lacs ・Standalone data |
|
|||||||||||
| Number of Owned Pharmaceutical Plants Number ・Standalone data |
||||||||||||
| Number of Permanent Employees Number ・Standalone data |
||||||||||||
| Reliance on Third-Party Manufacturing Binary (1=Yes, 0=No) ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14h - Submission of newspaper publication for financial results for the quarter and year ended March, 2026.
-
Announcement Under Regulation 30 (LODR) 2015- Authorization Of Kmps Under Regulation 30(5)
1d - Astal Laboratories authorized three KMPs for Regulation 30 materiality and stock exchange disclosures.
-
Announcement Under Regulation 30 (LODR), 2015- Re-Appointment Of Internal Auditor.
2d - M/s V R P S & Co. re-appointed internal auditors for FY 2026-27 on May 30, 2025.
-
Results- Financial Results For March 31, 2026
30 May - Resubmitted audited standalone and consolidated results for quarter/year ended 31 March 2026; unmodified audit opinion.
-
Compliance- Statement Of Deviation & Variation
30 May - Astal Labs filed Q4 FY2026 deviation report; no deviation, Rs306 lakh raised and Rs286 lakh utilized.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Update[1]
Astal Laboratories Limited (formerly Macro International Limited) was taken over in 2022 under SEBI takeover regulations, following which its objects were changed to manufacturing and sale of pharmaceutical intermediates and bulk drugs. The name was subsequently changed to Astal Laboratories Limited in May 2024.